575. Abacavir Use and Risk for Myocardial Infarction and Coronary Artery Disease: Updated Meta-analysis of Data from Clinical Trials Cassandra Nan, PhD; Mark S. Shaefer, PharMD; Rimgaile Urbaityte, MSc; James Oyee, MSc; Judy Hopking, MSc; Leigh Ragone, MS; Cynthia McCoig, PhD and Vani Vannappagari, MBBS, MPH, PhD; GlaxoSmithKline, Stevenage, United Kingdom, ViiV Healthcare, Research Triangle Pa...

A 14-year-old boy of African origin with HIV infection presented to the emergency department complaining of sore, swollen eyes and a sore throat. His antiretroviral treatment at that time consisted of lopinavir/ritonavir and abacavir/lamivudine fixed-dose combination. His plasma HIV RNA level has been undetectable for the past 2 years, and his CD4+ cell count has been consistently within the no...

575. Abacavir Use and Risk for Myocardial Infarction and Coronary Artery Disease: Updated Meta-analysis of Data from Clinical Trials Cassandra Nan, PhD; Mark S. Shaefer, PharMD; Rimgaile Urbaityte, MSc; James Oyee, MSc; Judy Hopking, MSc; Leigh Ragone, MS; Cynthia McCoig, PhD and Vani Vannappagari, MBBS, MPH, PhD; GlaxoSmithKline, Stevenage, United Kingdom, ViiV Healthcare, Research Triangle Pa...

Some of the latest developments in HIV treatment are described and contact information is given for people seeking further information on the topic. Clinical studies and preliminary results for interleukin-2 (IL-2), 1592U89 (abacavir), DMP-266 (efavirenz or Sustiva), and 141W94 (VX-94, Vertex) are described. Pharmaceutical companies are expected to continue developing new HIV drugs, including t...

575. Abacavir Use and Risk for Myocardial Infarction and Coronary Artery Disease: Updated Meta-analysis of Data from Clinical Trials Cassandra Nan, PhD; Mark S. Shaefer, PharMD; Rimgaile Urbaityte, MSc; James Oyee, MSc; Judy Hopking, MSc; Leigh Ragone, MS; Cynthia McCoig, PhD and Vani Vannappagari, MBBS, MPH, PhD; GlaxoSmithKline, Stevenage, United Kingdom, ViiV Healthcare, Research Triangle Pa...

Positive HLA-B*5701 genotype has recently been identified as the main genetic risk factor for flucloxacillin drug-induced liver injury (DILI). Testing for HLA-B*5701 is routine in many HIV clinics to identify those at risk of hypersensitivity reaction (HSR) to abacavir. Considering the high prevalence of soft-tissue infections in HIV patients, we conducted a retrospective study to investigate w...

A general and efficient synthesis of carbocyclic and hexenopyranosyl nucleosides has been developed. The strategy combines three key transformations: an asymmetric aldol addition to establish the relative and absolute configuration of the pseudosugar, a ring-closing metathesis to construct the pseudosugar ring, and a Trost-type palladium(0)-mediated substitution to assemble the pseudosugar and ...

Background Dyslipidemia in persons with HIV contributes significantly to cardiovascular (CV) risk. Abacavir (ABC) has been shown to increase lipid levels and some cohort studies have suggested an association between ABC use and myocardial infarction (MI). Comparative data suggested Truvada (TDF/FTC) has a lesser effect on lipid parameters than Kivexa [KVX]. We investigated the change in fasting...

575. Abacavir Use and Risk for Myocardial Infarction and Coronary Artery Disease: Updated Meta-analysis of Data from Clinical Trials Cassandra Nan, PhD; Mark S. Shaefer, PharMD; Rimgaile Urbaityte, MSc; James Oyee, MSc; Judy Hopking, MSc; Leigh Ragone, MS; Cynthia McCoig, PhD and Vani Vannappagari, MBBS, MPH, PhD; GlaxoSmithKline, Stevenage, United Kingdom, ViiV Healthcare, Research Triangle Pa...